Comparative Evaluation of the Effect of Prophylactic Intraligamentary Injection of Dexamethasone and Piroxicam on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-25

Study Completion Date

2019-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the study is conducted to assess and compare the efficacy of local intraligamentary injection of glucocorticoids(dexamethasone) and NSAID(piroxicam) on reduction of postoperative pain in patients with symptomatic irreversible pulpitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of a Prophylactic Intraligamentary Injection of Piroxicam Versus Mepecaine of Post-endodontic Pain

NCT03006107

Pulpitis - Irreversible

UNKNOWN NA

Intraligmentary Dexamethasone in Lower First Molars With Irreversible Pulpitis and Apical Periodontits

NCT05928611

Pulpitis - Irreversible

UNKNOWN NA

Comparison Between Intraligamentary Piroxicam and Articaine

NCT03612323

Pulpitis - Irreversible

UNKNOWN EARLY_PHASE1

Effect of Submucosal Cryotherapy on Postoperative Endodontic Pain

NCT06090500

Post-endodontic Pain

COMPLETED NA

Effect of Apical Patency and Local Corticosteroid on Pain and Neuropeptides Release in Patients With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial

NCT06457828

Postoperative Pain Symptomatic Irreversible Pulpitis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dexamethasone

Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)

Group Type EXPERIMENTAL

Dexamethasone sodium phosphate

Intervention Type DRUG

prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.

piroxicam

Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)

Group Type EXPERIMENTAL

Piroxicam Injectable Solution

Intervention Type DRUG

prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam

Mepivacaine HCL

Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)

Group Type ACTIVE_COMPARATOR

Mepivacaine HCL

Intervention Type DRUG

prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone sodium phosphate

prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.

Intervention Type DRUG

Piroxicam Injectable Solution

prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam

Intervention Type DRUG

Mepivacaine HCL

prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Systemically healthy patient (ASA I or II).
2. Mandibular Posterior teeth with:

* Preoperative sharp pain.
* Absence of widening in the periodontal ligament (PDL).
* Vital response of pulp tissue to cold pulp tester (ethyl chloride spray).

Exclusion Criteria

1. Patients allergic to anesthetics, piroxicam (any other NSAIDs) or dexamethasone (other corticosteroids).
2. Pregnant or nursing females.
3. Patients having significant systemic disorder (ASA III or IV).
4. Hemostatic disorders or anti-coagulant therapy during the last month.
5. Consumption of opioid or non-opioid analgesics or corticosteroids during the last 12 hrs before treatment.
6. Retreatment cases.

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes